Allakos (NASDAQ:ALLK), Inc. is a clinical-stage biotechnology company focused on developing novel therapies for allergic, inflammatory and proliferative diseases. The company’s approach centers on targeting Siglec-8, an inhibitory receptor found on eosinophils and mast cells, with monoclonal antibodies designed to modulate immune responses. By selectively dampening overactive pathways, Allakos aims to offer differentiated treatment options for patients with conditions driven by eosinophil and mast cell activity.
The company’s lead candidate, lirentelimab (AK002), is an anti-Siglec-8 antibody currently in late-stage clinical development for a range of indications, including chronic spontaneous urticaria, eosinophilic gastritis and eosinophilic esophagitis. Lirentelimab has demonstrated the potential to reduce symptoms and tissue inflammation by depleting eosinophils and inhibiting mast cell activation. In addition to its lead program, Allakos is advancing preclinical assets and exploring combination strategies to expand the therapeutic utility of its Siglec-8 platform.
Allakos conducts clinical trials across North America, Europe and other regions, collaborating with hospitals, research centers and patient advocacy groups to support enrollment and data collection. The company maintains partnerships with academic institutions and leverages its in-house expertise in antibody engineering, immunology and drug development to drive efficient advancement of its pipeline.
Founded in 2012 and headquartered in Redwood City, California, Allakos is led by a management team with extensive experience in immunology and biotechnology. The leadership group includes veteran researchers, clinicians and business executives who have played key roles in bringing novel therapies through clinical development and regulatory review. This depth of expertise underpins Allakos’s mission to address unmet medical needs in immune-mediated diseases.
